Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies

April 29, 2024 By Cade Hildreth, Founder & President Leave a Comment

Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.

Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.

[Read more…]

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

April 25, 2024 By Cade Hildreth, Founder & President Leave a Comment

Panasonic to create a closed-system manufacturing device based on Shinobi’s innovative iPS-T cell platform and cutting-edge research at Kyoto University

Partnership aimed at significantly broadening accessibility of cell therapies to patients on a global scale

SAN FRANCISCO and KYOTO, Japan, April 18, 2024 — Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University’s Center for iPS Cell Research and Application (CiRA). Through this strategic collaboration, the organizations aim to engineer a novel manufacturing platform to produce iPS-T cell therapies more efficiently and at lower cost than is possible with currently available technology. [Read more…]

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

April 8, 2024 By Cade Hildreth, Founder & President 1 Comment

Melbourne, Australia; 8 April 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). [Read more…]

Kenai Therapeutics Emerges with $82M to Advance Its Allogeneic, iPSC-Derived Therapy for Parkinson’s Disease

March 14, 2024 By Cade Hildreth, Founder & President Leave a Comment

Kenai Therapeutics has emerged from stealth mode with $82M to invest in its allogeneic iPSC-derived cell therapeutic for Parkinson’s disease (PD).

Proceeds to be used to complete clinical proof-of-concept trial for Kenai’s lead candidate, RNDP-001, for the treatment of Parkinson’s disease.

Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.